+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014-18

  • PDF Icon


  • 42 Pages
  • August 2019
  • Region: Global
  • Citeline
  • ID: 4846145
the author Strategy: Immuno-Oncology Deal Trends, 2014–18
  • Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is immuno-oncology.
  • Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body's natural ability to attack and fight off cancer.
  • Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under normal circumstances may be able to evade an immune system attack.
  • Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating lymphocytes, and vaccines.
  • As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.

Table of Contents

Table of Contents

  • Introduction
  • Immuno-Oncology Deal Volume
  • Deal Economics
  • Disease Analysis
  • Case Studies
  • Bibliography
  • Appendix